Cargando…
The CD112R/CD112 axis: a breakthrough in cancer immunotherapy
The recent discovery of immune checkpoint inhibitors is a significant milestone in cancer immunotherapy research. However, some patients with primary or adaptive drug resistance might not benefit from the overall therapeutic potential of immunotherapy in oncology. Thus, it is becoming increasingly c...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431939/ https://www.ncbi.nlm.nih.gov/pubmed/34507594 http://dx.doi.org/10.1186/s13046-021-02053-y |